ABVC BioPharma, Inc. (ABVC) AI Stock Analysis

• Market Cap: $13.12M
• Dividend Yield: N/A
• Average Volume (3M): 469.86K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.10
• Revenue Growth: 234.31%
• EPS Growth: 79.88%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 64
• Industry: Biotechnology
• EPS (TTM): -0.49
• Shares Outstanding: 15,778,305
• 10 Day Avg. Volume: 308,168
• 30 Day Avg. Volume: 469,861
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 17.56
• Price to Cash Flow (P/CF): 13.00
• P/FCF Ratio: 4.80
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

ABVC BioPharma faces significant financial challenges with persistent losses, high leverage, and poor cash flow management. Despite this, recent corporate events highlight substantial revenue growth and cost reductions, which could support future improvements. The technical analysis presents a neutral outlook with limited momentum, and the valuation remains unattractive due to the negative P/E ratio. Overall, the stock requires significant improvements in financial health and market sentiment for better prospects.

ABVC BioPharma, Inc. Business Overview & Revenue Model

Company Description

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.

How the Company Makes Money

ABVC BioPharma, Inc. generates revenue primarily through the development and commercialization of its proprietary drug candidates and medical devices. The company's revenue model includes licensing agreements, partnerships with other pharmaceutical companies, and potentially direct sales of successfully developed therapeutics and devices. Significant partnerships and collaborations with research institutions and healthcare organizations play a crucial role in advancing ABVC's product pipeline and can lead to milestone payments, royalties, and other income streams as products progress through clinical trials and receive regulatory approval.

ABVC BioPharma, Inc. Financial Statement Overview

Summary

ABVC BioPharma is struggling financially with consistent losses and negative cash flows. While there are slight improvements, high debt and poor profitability pose major challenges.

Income Statement

ABVC BioPharma shows consistent negative net income and EBIT margins, indicating ongoing profitability challenges. Revenue growth showed volatility with a significant decline in 2023, recovering slightly in the TTM period. Gross profit margin improved in TTM but remains insufficient to offset high operating losses.

Balance Sheet

The company's debt-to-equity ratio has improved but remains concerning due to high total debt levels. Equity ratio shows moderate stability, though stockholders' equity has fluctuated. The return on equity is negative due to persistent net losses.

Cash Flow

ABVC BioPharma's cash flow metrics reveal negative free cash flow growth and operating cash flow, indicating liquidity challenges. The free cash flow to net income ratio is unfavorable, reflecting difficulties in converting income to cash flow.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
509.79K	152.43K	969.78K	355.80K	483.05K	701.72K
	Gross Profit
360.95K	-149.61K	683.37K	350.71K	464.33K	681.58K
	EBIT
-6.33M	-8.22M	-15.11M	-11.35M	-8.51M	-3.46M
	EBITDA
-6.36M	-8.13M	-15.20M	-10.97M	-10.37M	-3.47M
	Net Income Common Stockholders
-8.24M	-10.52M	-16.31M	-12.04M	-10.59M	-3.93M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
0.00	139.47K	161.06K	5.94M	4.27M	144.29K
	Total Assets
275.71K	14.49M	9.86M	13.70M	11.61M	6.93M
	Total Debt
848.35K	2.28M	3.05M	3.11M	6.48M	4.58M
	Net Debt
848.35K	2.22M	2.97M	-2.72M	2.21M	4.44M
	Total Liabilities
2.84M	6.36M	6.24M	4.83M	8.94M	7.05M
	Stockholders Equity
-2.56M	8.39M	3.10M	8.84M	3.44M	-150.96K
Cash Flow		Free Cash Flow
-1.89M	-4.26M	-7.52M	-7.62M	-4.56M	-3.13M
	Operating Cash Flow
-1.91M	-4.24M	-7.40M	-7.60M	-4.56M	-3.13M
	Investing Cash Flow
154.17K	-360.19K	-1.72M	-805.97K	-225.43K	-35.30K
	Financing Cash Flow
1.62M	3.92M	4.01M	10.00M	9.57M	3.09M

ABVC BioPharma, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.91
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABVC, the sentiment is Positive. The current price of 0.91 is below the 20-day moving average (MA) of 0.92, above the 50-day MA of 0.75, and above the 200-day MA of 0.65, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 51.57 is Neutral, neither overbought nor oversold. The STOCH value of 18.49 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABVC.

ABVC BioPharma, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.20B	3.26	-40.34%	2.93%	17.68%	1.94%
BOLT	44 Neutral	$14.91M	―	-74.28%	―	-2.36%	9.68%
COCP	43 Neutral	$14.15M	―	-97.50%	―	―	9.46%
SABS	43 Neutral	$13.93M	―	-81.92%	―	-40.94%	51.90%
ABVC	43 Neutral	$13.12M	―	-97.42%	―	234.31%	79.88%
PHGE	42 Neutral	$13.96M	―	-189.64%	―	―	45.24%

ABVC BioPharma, Inc. Corporate Events

ABVC BioPharma Reports Strong Financial Growth

In 2024, ABVC BioPharma experienced a transformative year with a 234% increase in revenue, reaching $509,589, primarily due to milestone payments from global licensing partners. The company also reduced operating expenses by 21% and improved its earnings per share by 77%, reflecting strong execution and cost discipline. With over $18.3 million in potential milestone payments remaining, ABVC is well-positioned for future growth without relying on dilutive financing.

Spark’s Take on ABVC Stock

According to Spark, TipRanks’ AI Analyst, ABVC is a Underperform.

ABVC BioPharma has significant financial issues, including persistent losses and high leverage, which are the primary factors for its low score. Technical analysis indicates lack of upward momentum, and the valuation is unattractive due to a negative P/E ratio. Improvement in financial health and market sentiment is crucial for better prospects.

To see Spark’s full report on ABVC stock, click here.